Renal cell carcinoma with metastases to the external genitalia. Literature review and case report

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2021-07-25 DOI:10.17650/1726-9776-2021-17-2-174-181

K. Menshikov, A. V. Sultanbaev, S. Musin, A. A. Izmaylov, R. R. Muginov, I. Menshikova, I. A. Sharifgaleev, D. Lipatov, N. Sultanbaeva

{"title":"Renal cell carcinoma with metastases to the external genitalia. Literature review and case report","authors":"K. Menshikov, A. V. Sultanbaev, S. Musin, A. A. Izmaylov, R. R. Muginov, I. Menshikova, I. A. Sharifgaleev, D. Lipatov, N. Sultanbaeva","doi":"10.17650/1726-9776-2021-17-2-174-181","DOIUrl":null,"url":null,"abstract":"Annually, up to 300 thousand new cases of kidney cancer and more than 134 thousand deaths associated with this disease are registered in the world. In the Russian Federation in 2019, 20,758 patients with a newly diagnosed renal cell carcinoma were registered; it should be noted that at the end of 2019, 177,755 patients with this diagnosis were registered. The issue of renal cell carcinoma metastasis seems to be quite relevant. The most common organs for metastatic renal cell carcinoma are lungs (up to 55 %), lymph nodes (up to 34 %), liver (up to 32 %), bones (up to 32 %), adrenal glands (up to 19 %), contralateral kidney (up to 11 %) and the brain (up to 5.7 %). The incidence of skin metastases in renal cell carcinoma ranges from 2.8 to 6.8 %, according to various authors.Our publication presents a case of treatment of a patient with a rare localization of renal cell carcinoma metastases in the external genital organs. The patient underwent palliative nephrectomy and vulvectomy. Taking into account the data on the prevalence of the disease, therapy with cabozantinib is carried out. Cabosantinib is an inhibitor of the tyrosine kinase domains of a number of growth factors, angiogenesis, abnormal bone remodeling, metastasis, and drug resistance.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2021-17-2-174-181","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Annually, up to 300 thousand new cases of kidney cancer and more than 134 thousand deaths associated with this disease are registered in the world. In the Russian Federation in 2019, 20,758 patients with a newly diagnosed renal cell carcinoma were registered; it should be noted that at the end of 2019, 177,755 patients with this diagnosis were registered. The issue of renal cell carcinoma metastasis seems to be quite relevant. The most common organs for metastatic renal cell carcinoma are lungs (up to 55 %), lymph nodes (up to 34 %), liver (up to 32 %), bones (up to 32 %), adrenal glands (up to 19 %), contralateral kidney (up to 11 %) and the brain (up to 5.7 %). The incidence of skin metastases in renal cell carcinoma ranges from 2.8 to 6.8 %, according to various authors.Our publication presents a case of treatment of a patient with a rare localization of renal cell carcinoma metastases in the external genital organs. The patient underwent palliative nephrectomy and vulvectomy. Taking into account the data on the prevalence of the disease, therapy with cabozantinib is carried out. Cabosantinib is an inhibitor of the tyrosine kinase domains of a number of growth factors, angiogenesis, abnormal bone remodeling, metastasis, and drug resistance.

查看原文本刊更多论文

转移到外生殖器的肾细胞癌。文献复习及病例报告

每年，世界上登记的肾癌新病例多达30万例，与此疾病相关的死亡人数超过13.4万。2019年，俄罗斯联邦登记了20,758名新诊断的肾细胞癌患者;值得注意的是，截至2019年底，共有177755名患者登记了这一诊断。肾细胞癌转移的问题似乎是相当相关的。转移性肾细胞癌最常见的器官是肺(高达55%)、淋巴结(高达34%)、肝脏(高达32%)、骨骼(高达32%)、肾上腺(高达19%)、对侧肾脏(高达11%)和脑(高达5.7%)。根据不同作者的说法，肾细胞癌皮肤转移的发生率从2.8到6.8%不等。我们的出版物提出了一个病例的治疗病人罕见的定位肾细胞癌转移到外生殖器器官。患者行姑息性肾切除术及外阴切除术。考虑到疾病流行的数据，使用卡博赞替尼进行治疗。卡博桑替尼是一种酪氨酸激酶结构域的抑制剂，抑制多种生长因子、血管生成、异常骨重塑、转移和耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.